Navivest Stocks and Options Blog » glaxosmithkline http://www.navivest.com/blog Stocks and options trading ideas and market commentary. Tue, 07 Sep 2010 10:03:44 +0000 en hourly 1 Xenoport Down 64% In Pre-Market Trading http://www.navivest.com/blog/2010/02/xenoport-64-premarket-trading/ http://www.navivest.com/blog/2010/02/xenoport-64-premarket-trading/#comments Thu, 18 Feb 2010 14:10:25 +0000 Navivest http://www.navivest.com/blog/?p=22 Xenoport (XNPT), a biopharmaceutical company, is seeing its shares drop 64.29% in pre-market trading, going from $19.60 to $7.00, after the company announced that a drug that was developed by it and a partner GlaxoSmithKline (GSK) had been denied approval by the Food and Drug administration.

The drug, Horizant, was being developed to treat restless leg syndrome.

]]> http://www.navivest.com/blog/2010/02/xenoport-64-premarket-trading/feed/ 0